The role of intraperitoneal therapy in advanced ovarian cancer

Lisa M. Hess, David S. Alberts

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations

Abstract

Intraperitoneal (IP) chemotherapy is a preferred treatment option that should be offered to all women for front-line treatment of stage III optimally debulked ovarian cancer. Patients should be provided with information on the survival and toxicity for both IP and intravenous (IV) therapies, as well as practical information about the administration of each regimen, so that they may play an active role in the decision-making process. When making a decision between IP and IV therapeutic options, the experience and preference of the oncologist are critical factors in determining appropriate therapy for each woman.

Original languageEnglish (US)
Pages (from-to)227-232
Number of pages6
JournalONCOLOGY
Volume21
Issue number2
StatePublished - Feb 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The role of intraperitoneal therapy in advanced ovarian cancer'. Together they form a unique fingerprint.

Cite this